Disorder of glycogen metabolism
MONDO:0002412An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.
Also known as: GSD, glycogen storage disease, glycogen storage disorder, glycogenoses, glycogenosis, inborn error of glycogen metabolic process, inborn glycogen metabolic process disorder, inborn glycogen storage disorder
69 clinical trials for this condition and its sub-types, 15 tagged with Disorder of glycogen metabolism itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Disorder of glycogen metabolism
-
Glycogen storage disease II 31 trials · 41 incl. sub-types
-
Glycogen storage disease I 10 trials · 13 incl. sub-types
3 sub-types
- Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 7 trials
- Glycogen storage disease type 1 due to SLC37A4 mutation 0 trials · 3 incl. sub-types Sub-types →
- Glycogen storage disease Id 0 trials
-
Danon disease 5 trials
-
Glycogen storage disease IX 2 trials · 3 incl. sub-types
4 sub-types
- Glycogen storage disease IXa1 2 trials
- Glycogen storage disease IXa2 2 trials
- Glycogen storage disease IXb 2 trials
- Glycogen storage disease IXc 2 trials
-
Glycogen storage disease III 2 trials
-
Glycogen storage disease V 2 trials
-
Glycogen storage disease VI 2 trials
-
8 sub-types
- Adult polyglucosan body disease 1 trial
- Glycogen storage disease due to glycogen branching enzyme deficiency, adult neuromuscular form 0 trials
- Glycogen storage disease due to glycogen branching enzyme deficiency, childhood combined hepatic and myopathic form 0 trials
- Glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form 0 trials
- Glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form 0 trials
- Glycogen storage disease due to glycogen branching enzyme deficiency, fatal perinatal neuromuscular form 0 trials
- Glycogen storage disease due to glycogen branching enzyme deficiency, non progressive hepatic form 0 trials
- Glycogen storage disease due to glycogen branching enzyme deficiency, progressive hepatic form 0 trials
-
Glycogen storage disease due to liver phosphorylase kinase deficiency 0 trials · 2 incl. sub-types
2 sub-types
- Glycogen storage disease IXa1 2 trials
- Glycogen storage disease IXc 2 trials
-
Lafora disease 1 trial
2 sub-types
- Myoclonic epilepsy of Lafora 1 0 trials
- Myoclonic epilepsy of Lafora 2 0 trials
-
Glycogen storage disease VII 1 trial
-
GYG1-related disorder of glycogen metabolism 0 trials · 1 incl. sub-types
2 sub-types
- Polyglucosan body myopathy type 2 1 trial
- Glycogen storage disease XV 0 trials
-
Glycogen storage disease IXd 0 trials
-
1 sub-type
Most studied deeper sub-types
-
New pompe disease drug moves to first human tests
Disease control CompletedThis early-phase study tested a new drug called ABX1100 in 46 people, including healthy volunteers and patients with late-onset Pompe disease. The main goal was to check safety and how the drug moves through the body. Researchers gave single or multiple doses to find the right am…
Early phase 1 • Sponsor: Aro Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Gene therapy hope for pompe patients in early safety trial
Disease control CompletedThis early-phase study tested a new gene therapy called ACTUS-101 in 7 adults with late-onset Pompe disease. The main goal was to check safety and side effects. Participants received a single intravenous dose, and researchers monitored their health over time.
Phase 1 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Gene therapy could free GSD ia patients from constant cornstarch
Disease control CompletedThis Phase 3 trial tested a gene therapy called DTX401 in 49 people with glycogen storage disease type Ia (GSD Ia). The goal was to see if a single infusion could reduce or eliminate the need for frequent cornstarch doses to keep blood sugar stable. Participants were randomly ass…
Phase 3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene therapy for rare Sugar-Storage disease shows promise in Long-Term safety check
Disease control CompletedThis study checked the long-term safety of a one-time gene therapy (DTX401) in 12 adults with glycogen storage disease type Ia, a rare condition that causes dangerously low blood sugar. Researchers monitored side effects and how well the therapy helped control blood sugar levels …
Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Pompe disease drug combo shows Long-Term safety in phase 3 trial
Disease control CompletedThis study tested the long-term safety of a combination therapy (ATB200 and AT2221) in 119 adults with late-onset Pompe disease who had completed a prior study. Participants received the drugs for an extended period, and researchers tracked side effects, walking distance, and lun…
Phase 3 • Sponsor: Amicus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo shows promise for rare pompe disease
Disease control CompletedThis study tested whether a new combination of two drugs (ATB200 and AT2221) is safe for adults with Pompe disease, a rare genetic disorder that causes muscle weakness. 29 participants received the drugs through an IV and by mouth. The main goal was to check for side effects and …
Phase 1/2 • Sponsor: Amicus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug cocktail aims to boost walking and breathing in pompe patients
Disease control CompletedThis phase 3 trial tested a new treatment for adults with late-onset Pompe disease, a rare genetic disorder that weakens muscles and breathing. Participants received either the experimental combo (cipaglucosidase alfa plus miglustat) or the current standard therapy (alglucosidase…
Phase 3 • Sponsor: Amicus Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 16:41 UTC
-
Can a smarter glucose monitor stop dangerous lows? small study tests predictive alerts
Symptom relief CompletedThis completed study tested whether a continuous glucose monitor with predictive alerts (Dexcom G7) can reduce low blood sugar better than a standard alert monitor (Dexcom ONE+) in 11 adults with glycogen storage disease or congenital hyperinsulinism. Participants wore each devic…
Sponsor: University Hospital Padova • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Robotic leg device shows promise for helping muscle disease patients walk
Symptom relief CompletedThis study tested a powered leg exoskeleton (Keeogo) in 50 people with various muscle disorders to see if it is safe and helps them walk better. Participants performed walking tests with and without the device. The goal was to see if the device could improve walking distance and …
Sponsor: Institut de Myologie, France • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Robotic exoskeleton shows promise for muscle disease patients
Symptom relief CompletedThis study tested a wearable robotic suit called MyoSuit that assists knee and hip movement in people with various muscle disorders. 32 participants used the device to perform walking tests, and researchers checked for safety and any immediate improvements in walking ability. The…
Sponsor: Institut de Myologie, France • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Home breathing training shows promise for pompe patients
Symptom relief CompletedThis study tested whether high-dose inspiratory muscle training (IMT) using a handheld device is safe and feasible for people with late-onset Pompe disease. 34 adults with stable Pompe disease did remote breathing exercises. Researchers measured changes in respiratory strength an…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Dietary oil shows promise for rare muscle disorder
Symptom relief CompletedThis study tested whether a dietary oil called triheptanoin can improve exercise capacity in adults with McArdle disease, a rare genetic disorder that affects how muscles use stored sugar. Twelve participants received either triheptanoin or a placebo oil for two weeks, then switc…
Phase 2 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Symptom relief
Last updated Jun 26, 2026 13:57 UTC
-
Pompe disease may raise risk of brain aneurysms, new study investigates
Knowledge-focused CompletedThis study investigates whether people with late-onset Pompe disease have a higher risk of severe blood vessel problems in the brain and aorta. Researchers will collect medical and genetic data from adults with Pompe disease and from those who have had a brain aneurysm or bleedin…
Sponsor: Hospitales Universitarios Virgen del Rocío • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Heart condition costs under the microscope in massive hospital study
Knowledge-focused CompletedThis study collected information from over 15,000 people hospitalized with cardiomyopathy, a heart muscle disease. Researchers looked at how much these hospital stays cost and what the money was spent on. The goal was to understand the real-world financial impact and help manage …
Sponsor: China National Center for Cardiovascular Diseases • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Scientists hunt for missing genetic clues in mystery diseases
Knowledge-focused CompletedThis study aimed to find new genetic changes that might cause inherited diseases, especially in people who already have a diagnosis but whose genetic tests were not clear. Researchers studied 56 patients and their family members to look for hidden variants in parts of the DNA tha…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Can a breath test reveal how muscles make energy? tiny study explores new way to track treatment effects
Knowledge-focused CompletedThis small pilot study looked at whether simple breath and urine tests can measure how well muscles produce energy in children with metabolic myopathies (rare muscle disorders). Three participants completed a 12-week at-home physiotherapy program. The goal was to see if these non…
Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC